durvalumab

News

After looking like it could get left far behind by rivals in immunotherapy, AstraZeneca has made its first filing for PD-L1 drug durvalumab .

News

US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.